Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:12/12/2008

VIENNA, Va., Dec. 12 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (NYSE Alternext US: CVM) to its shareholders:

Dear Fellow Shareholders:

Recently we have had two pieces of important news for CEL-SCI Corporation and its shareholders. First, the U.N. World Health Organization's Agency for Research on Cancer report, in reference to the "cancer burden" wrote that "the global burden doubled in the last 30 years of the 20th Century, and it is estimated that this will double again between 2000 and 2020 and nearly triple by 2030". Cancer will soon become the Number One killer in the world, ahead of heart disease. Those increases are much greater than many people had expected and clearly make our non-toxic Multikine cancer product even more important to develop. Second, we need your help with a legislative proposal advocated by the Biotechnology Industry Organization (BIO) which would help CEL-SCI bring Multikine to market faster. Last, what percentage of people do you think will get cancer and how many of them will die from it? The answer may shake you (see below).

    In this letter I also want to review the general status of our Multikine cancer drug:

        1. In the last few months we have hit major milestones.  We signed a
           Multikine licensing agreement with Teva Pharmaceuticals, a
           multinational pharmaceutical company, which will participate in
           and pay for part of our Phase III trial, we took delivery of our
           new manufacturing facility in Baltimore (see the pictures at
           www.cel-sci.com and click on Updated Pictures of Manufacturing
           Facility), and we extended our existing Multikine partnership with
           Orient Europharma (OEP) of Taiwan to cover a larger territory.
           OEP, like Teva, will participate in and pay for part of the Phase
           III clinical t
'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
(Date:9/2/2015)... Whitehouse, NJ (PRWEB) , ... September 02, 2015 ... ... key Technical Services Staff members will be attending Pharma Ed Resources upcoming ... and respected group of industry leading speakers, this timely conference will provide Updates ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Wilson , an 18-year GE veteran, was promoted to president ... May to replace Gregory Lucier, who left to become CEO ... most of GE Medical's monitoring systems . , ,It's a ... growth opportunity (GE Medical is about $9 billion and produced ...
... - With Sony set to take over Sonic Foundrys desktop ... go from here? Two words: Mediasite Live. , ,Sonic ... audio conferencing market by enhancing web conferencing with Mediasite Live. ... great opportunity for the company to go forward because there ...
... employee scheduling and management products. The company was the ... Suite Scheduler, a former nurse manager frustrated with the ... facility. , ,Suite Scheduler products are able to improve ... of the time to create and manage employee schedules ...
Cached Biology Technology:CEO Wilson Defines GE's Health-IT Customer 2CEO Wilson Defines GE's Health-IT Customer 3CEO Wilson Defines GE's Health-IT Customer 4Sonic Foundry: What's Next? 2Scheduling made easy with Suite Scheduler 2Scheduling made easy with Suite Scheduler 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... work, home or elsewhere results in a disproportionate rise ... University of Nottingham researchers have found. , A new ... Heart Association, measured the level of cotinine in participants' ... to second-hand smoke. Cotinine is the major metabolite of ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
... with a knowledge of the properties and actions of enzymes, ... anti-cancer drugs originally isolated from blue-green algae. , This ... of the promising drugs for use in clinical trials. ... January issue of the journal ACS Chemical Biology, a scientific ...
Cached Biology News:Indicators for risk of heart disease are higher in passive smokers 2Indicators for risk of heart disease are higher in passive smokers 3MU researcher placing eye implants in cats to help humans see 2Turning green gunk to gold, anti-cancer gold 2
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
...
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: